Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 20+ pipeline drugs in the Narcolepsy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
“Narcolepsy Pipeline Insight, 2023” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Narcolepsy Therapeutics Market.
The report provides a detailed description of the Narcolepsy drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
The report provides insights into:
- The report provides detailed insights into the key companies that are developing Narcolepsy therapies.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Narcolepsy treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging Narcolepsy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Narcolepsy treatment market.
Request for Sample PDF to Learn More @ Narcolepsy Treatment Outlook and Future Perspectives
The Report Covers the Emerging Narcolepsy Therapies Under Different Phases of Clinical Development Like –
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Narcolepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Learn How the Therapeutics Segment Will Evolve in the Upcoming Years @ Narcolepsy Clinical and Commercial Development Activities
Narcolepsy Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Narcolepsy. Currently, Avadel Pharmaceuticals is leading the therapeutics market with its Narcolepsy drug candidates in the most advanced stage of clinical development.
Narcolepsy Companies in the Therapeutics Market Include:
- Axsome Therapeutics, Inc.
- Avadel Pharmaceuticals
- Suven Life Sciences
- Takeda
- NLS Pharmaceutics
- Vallon Pharmaceuticals
- Alkermes
- Centessa Pharmaceuticals
- Ono Pharma
- Harmony Biosciences
- Reset Therapeutics
- XWPharma
- Sunovion Pharmaceuticals
- Otsuka Pharmaceutical
- ConSynance Therapeutics
- Alkermes
- KemPharm
And Many Others
Emerging and Marketed Narcolepsy Therapies Covered in the Report Include:
- FT218: Avadel Pharmaceuticals
- AXS-12: Axsome therapeutics
- BTD-001: Balance Therapeutics
- JZP-258: Jazz Pharmaceuticals
- Xyrem: Jazz Pharmaceuticals
- TS-091: Taisho Pharmaceutical
- THN102: Theranexus
- Pitolisant: Bioprojet Pharma
And Many More
Get an in-depth Assessment of the Therapies and Key Players @ Narcolepsy Emerging Therapies and Companies
Table of Content
- Report Introduction
- Executive Summary
- Narcolepsy Current Treatment Patterns
- Narcolepsy – DelveInsight’s Analytical Perspective
- Therapeutic Assessment
- Narcolepsy Late-Stage Products (Phase-III)
- Narcolepsy Mid-Stage Products (Phase-II)
- Early Stage Products (Phase-I)
- Pre-clinical Products and Discovery Stage Products
- Inactive Products
- Dormant Products
- Narcolepsy Discontinued Products
- Narcolepsy Product Profiles
- Narcolepsy Companies
- Narcolepsy Drugs
- Dormant and Discontinued Products
- Narcolepsy Unmet Needs
- Narcolepsy Future Perspectives
- Narcolepsy Analyst Review
- Appendix
- Report Methodology
Get Detailed Insights About the Reports Offerings @ Narcolepsy Pipeline Insights
Related Report by DelveInsight:
“Narcolepsy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Narcolepsy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Some of the key companies such as Avadel Pharmaceuticals, Axsome therapeutics, Balance Therapeutics, Jazz Pharmaceuticals, Taisho Pharmaceutical, Theranexus, Bioprojet Pharma others are actively work in the Narcolepsy Market.
Narcolepsy Epidemiology Forecast
“Narcolepsy Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Narcolepsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
“Cataplexy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cataplexy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Some of the key companies such as Avadel, Axome Therapeutics, and others are actively working in the Cataplexy Market.
Excessive Daytime Sleepiness (EDS) Market
“Excessive Daytime Sleepiness Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Excessive Daytime Sleepiness market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Some of the key companies such as Balance Therapeutics, Takeda Pharmaceuticals, Benevolent AI Bio, Avadel Pharmaceuticals, Axsome Therapeutics, and others are actively working in the market.
The global sleep tech devices market was valued at USD 16,941.46 million in 2022, growing at a CAGR of 17.31% during the forecast period from 2023 to 2028 to reach USD 44,038.42 million by 2028. Some of the key companies such as Koninklijke Philips N.V, Huawei Device Co Ltd., ResMed, Xiaomi, Apple Inc., Emfit Corp., Masimo, Garmin Ltd., Compumedics Limited, NIHON KOHDEN CORPORATION, Cadwell Industries Inc., Eight Sleep, Oura Health Oy, Sleep Shepherd LLC, Sleepace, Apollo Neuroscience Inc., Braebon Medical Corporation, Belun Technology, Nyxoah, Somnology, Inc., and others working in the Sleep Tech Devices Market.
Other Trending Healthcare Reports by DelveInsight:
Invasive Pneumococcal Disease Market | Hepatic Impairment Market | Papilloma Market | Chronic Idiopathic Constipation Market | Hematuria Market | Optic Neuropathy Market | Urinary Incontinence Market | Negative Pressure Wound Therapy Systems Market | Open-Angle Glaucoma Market | Bronchial Hyperreactivity Market | Cytokine Release Syndrome Market | Dental Lasers Market | Down Syndrome Market | Extracorporeal Circulation System Market | Failed Back Surgery Syndrome Market | Germ Cell Tumor Market | India Healthcare Outlook | Indolent Lymphoma Market | Insulin Glargine Biosimilar | Lipodystrophy Market | Listeriosis Market | Liver Angiosarcoma Market | Mucopolysaccharidosis I Market | Nasolabial Fold Market | Neuroleptic Malignant Syndrome Market | Pachyonychia Congenita Market | Pegfilgrastim Biosimilar | Point of Care Glucose Testing Market | Singapore Healthcare Outlook | Substance (Drug) Abuse Market | Synchronous Endometrial and Ovarian Cancer (SEOC) Market | Trastuzumab Biosimilars | Urinary Tract Infection Devices Market | Varicose Veins Market | Vutrisiran Market
Leverage the potential of consulting services to overcome the competition in the highly evolving and dynamic healthcare market with Healthcare Regulatory Analysis and Merger and Acquisitions in Healthcare Industry
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
Manager (Marketing & Branding)
info@delveinsight.com
+1(919)321-6187.